Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 11/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24070901 | 0.92 | DNM1 (0.36) | DNM1TSHR | |
| Trimethylammonium SCHEMBL6037158 | 0.81 | DNM1 (0.39) | DNM1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL1051882 | 0.80 | DNM1 (0.40) | DNM1TSHRTHRBFDPSGGPS1 | |
| Trimethylammonium SCHEMBL27922076 | 0.79 | TSHR (0.44) | DNM1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL18743796 | 0.78 | DNM1 (0.44) | DNM1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL6063824 | 0.78 | TSHR (0.47) | TSHRTHRBFDPSGGPS1CES2 | |
| SCHEMBL20856453 | 0.75 | TSHR (0.53) | TSHRTHRBFDPSGGPS1CES2 | |
| SCHEMBL20856500 | 0.75 | TSHR (0.53) | TSHRTHRBFDPSGGPS1CES2 | |
| SCHEMBL20856432 | 0.75 | TSHR (0.53) | TSHRTHRBFDPSGGPS1CES2 | |
| SCHEMBL20856434 | 0.75 | TSHR (0.53) | TSHRTHRBFDPSGGPS1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | DNM1 2533/4885TSHR 1458/4885THRB 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.